AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05755061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEMS Plus
Description: 12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS
Study NCT05755061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GEMS
Description: 12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS
Study NCT06399497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: simulated manipulation
Description: Simulated manipulation intervention, in the same position as in the Intervention Group, performance in right lateral decubitus with the left leg flexed and the left foot resting on the right popliteal fossa. Without stretching the paravertebral tissues, the participant will remain for approximately 20 seconds without receiving manual impulse.
Study NCT05659160 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular Therapy
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.
Study NCT04475705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60
Study NCT04475705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
Study NCT04995874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KOKOPlus protein and micronutrient powder
Description: KokoPlus, a complementary food supplement was formulated by using linear programming methodology to improve the protein quality as well as the micronutrient and macronutrient content of commonly consumed traditional complementary (baby) foods in Ghana . It contains soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix. It complies with WHO's complementary feeding guidelines, FAO/WHO recommended micronutrient intake (RNI) and the WHO's guidelines for protein and essential amino acid intake for children in the age group of 6 to 24 months. A daily supply of KokoPlus achieves 30% of the total recommended energy, 60% of total protein and 40% of total fat requirements from complementary foods. It also meets 35-55% of minimum intake of essential amino acids and 50-150% RNI based on the total daily requirements.
Study NCT04871191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.
Study NCT04871191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Subcutaneous injection of 162 mg per week
Study NCT04871191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Subcutaneous injection of 125 mg per week
Study NCT06333600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical minoxidil
Description: Therapeutic intervention
Study NCT06333600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Vitamin D
Description: Therapeutic intervention
Study NCT06333600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: placebo
Study NCT05296590 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte Distribution Width (MDW) , observation
Description: Observation of MDW performance blinded to treating clinical teams
Study NCT05260918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Float-REST
Description: Participants will utilize sensory deprivation tanks.
Study NCT05260918 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nappod
Description: Participants will utilize nappod.
Study NCT04590833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised walking on a treadmill
Description: Each participant will be provided with an individualized target heart rate zone based on his/her age. Heart rate during exercise will be measured using a finger pulse oximeter. Following baseline measures, participants will receive instructions on how to use a finger pulse oximeter by a student. For participants who are not physically fit or are just engaging in regular exercise, they will be advised to start walking on a treadmill at a comfortable pace for 5 to 10 minutes at one time.46 Exercise duration and intensity will be progressed from week 3 to week 5, until participants will walk at 40-59% of heart rate reserve based on their age, which will be maintained throughout the study.
Study NCT04590833 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supervised stretching exercise
Description: Following baseline measures, a student will demonstrate the use of a pulse oximeter and stretching movements to these participants. Starting on week 3, participants will do the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise. Stretching will target all major muscle-tendon groups including shoulder, chest, neck, truck, lower back, hips, and legs. It will also involve a slow and constant motion that accounts for any physical limitations and physician-specified precautions
Study NCT05982262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naturopathic-pharmacological consultation
Description: The naturopathic-pharmacological consultation includes a naturopath and a clinical pharmacist and will consist of at least two meetings.
Study NCT04107389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Art Psychotherapy, Art Therapy
Description: Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.
Study NCT04107389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait List
Description: Wait list control group. Participants randomised to Wait List group or Intervention group.
Study NCT04608539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose
Description: Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1
Study NCT04608539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up
Study NCT04608539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Single-dose infusion (placebo), postoperative day 1
Study NCT04865926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular and Neck Proprioceptive Neuromuscular Facilitation exercises
Description: The researcher will perform a total of 12 sessions of scapular and neck pnf exercises for 4 weeks. The participants will apply PNF exercises using rhythmic initiation, rhythmic stabilization and cobination techniques of isotonics. Patterns of anterior elevation, posterior depression, anterior depression, posterior elevation will be used in scapular exercises. Upper cervical flexion, lower cervical flexion, rotation and lateral flexion patterns will be used in neck pnf exercises.
Study NCT04865926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie and Kendall exercises
Description: Kendall and Mckenzie exercises will be given to the participants as a home workout. The self-stretch exercise methods are as followed: Placing both hands on the shoulders and pushing out the chest, placing one hand over the shoulder and grasp the elbow of the turned hand, with the other hand over the head and slowly pull it inward, throwback the head until it has reached the fully stretched point, look straight ahead and slowly turn the head horizontally until the maximum value is reached, throwback the head, and turn it until it has reached the fully stretched point, lower the head turn it until it has reached the maximal point. Stretching pectoralis muscle, strengthening shoulder retraction, strengthening the deep cervical flexors, strengthening the deep cervical flexors.
Study NCT06271278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: Emotional Freedom Technique (EFT) is a powerful and effective practice that enables individuals to release negative emotions and achieve mental and physical relaxation. EFT is a form of counselling based on acupuncture points, which are areas of low electrical and energy flow in the body. Stimulating these points causes the brain to secrete dopamine. EFT involves stimulating specific points on the body where energy flow is low. This is done by gently tapping on these areas with the fingers, which releases dopamine. The process is painless and can be performed by the individual themselves.
Study NCT06551246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: According to randomization.
Study NCT06551246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: According to randomization.
Study NCT05559723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electromagnetic field therapy
Description: Three times a week for four weeks, the study group got electromagnetic fields (EMFs) therapy and the selected physical therapy program. The EMFs therapy was applied using an electromagnetic field therapy device (Magner Plus Astar)~. From the prone lying position the device will be adjusted around the lumbar area at a low frequency (50 Hz), with the intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60), and the application time will be10 minutes
Study NCT05559723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Description: in the form of~1. Hot packs will be placed paravertebral on the lumbar region for 5 minutes from a prone lying position~2. selected physical therapy exercises in form of Static exercise for back and abdominal muscles, stretching exercises for both lower limbs, 10 times each exercise
Study NCT05559723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound therapy
Description: Therapeutic ultrasound therapy using ultrasound device Chattanooga, model 2760, serial number T11238, 120-240V, 50/60Hz, made in Mexico . That will be applied paravertebral on the lumbar region from the prone lying position, with pulsed mode, frequency 1 MHz, intensity 0.5 W/cm2 and will be applied by circular moving technique at a rate of 4 cm/s for 10 minutes.
Study NCT05559723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Transcutaneous Electrical Nerve Stimulation (TENS): from the prone lying position, the electrodes will be placed on the course of pain detected by the patient, with an asymmetrical rectangular biphasic form, at a pulse repetition frequency of 100Hz and duty cycle of 250 microseconds; the intensity was set at a level that each patient could feel, for 15 minutes .
Study NCT05000346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug, inhalation
Description: Solution administered by inhalation
Study NCT05000346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug, inhalation
Description: Solution administered by inhalation
Study NCT06107010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the Atalante exoskeleton
Description: Six weeks of exoskeleton sessions replacing conventional therapy sessions three times a week
Study NCT05205408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection(RT-01)
Description: Administered by intratumoral injection as single agent.
Study NCT04702009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 Monoclonal Antibody，Chemotherapy
Description: Anti-PD-1/PD-L1 monoclonal antibody (approved anti-PD-1/PD-L1 monoclonal antibody)；albumin paclitaxel/docetaxel + carboplatin (albumin paclitaxel 130mg/m2, d1 d8, Docetaxel 75mg/m2, carboplatin AUC=5, d1, every 21 days, 4 cycles of chemotherapy; immunotherapy no more than 2 years)
Study NCT04702009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1/PD-L1 Monoclonal Antibody，Chemotherapy
Description: Anti-PD-1/PD-L1 monoclonal antibody (approved anti-PD-1/PD-L1 monoclonal antibody)；albumin paclitaxel/docetaxel + carboplatin (albumin paclitaxel 130mg/m2, d1 d8, Docetaxel 75mg/m2, carboplatin AUC=5, d1, every 21 days, 4 cycles of chemotherapy; immunotherapy no more than 2 years)
Study NCT04702009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy-assisted Interventional Therapy
Description: Bronchoscopy-assisted interventional therapy (1 time before chemotherapy or 2 times before chemotherapy and before the third cycle of treatment)
Study NCT05350462 — intervention group
Intervention type: BEHAVIORAL
Intervention: Community pilot L-PZQ distribution - intervention is NOT part of this observational study
Description: Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.
Study NCT06772753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive substance
Study NCT06772753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: active comparator for psychedelic effects
Study NCT06772753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: psychoactive substance
Study NCT06772753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM)
Description: psychoactive substance
Study NCT06772753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyltryptamine (DMT)
Description: psychoactive substance
Study NCT06772753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylenedioxymethamphetamine (MDMA)
Description: psychoactive substance
Study NCT06772753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC)
Description: psychoactive substance
Study NCT06773273 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CapsuLaser-Assisted Capsulorhexis and Flanged Prolene Suture
Description: CapsuLaser-Assisted Capsulorhexis and Flanged 6-0 Prolene Suture for Cionni Ring Scleral Fixation
Study NCT04774965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slumber Curve sleep aid
Description: Patients who undergo rotator cuff repair and have been consented and randomized to the experimental group will be given a Slumber Curve sleep aid to be used during sleep. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Slumber Curve, patients will be given instructions on how to use the sleep aid while sleeping, and will be asked to use Slumber Curve nightly.
Study NCT06772376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SERS sensor based on CHA reaction
Description: 1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
Study NCT06772935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: A method of acupuncture that combines acupuncture with a certain frequency of electrical stimulation. Electrical stimulation is a mild level of stimulation intensity that is acceptable to the human body.
Study NCT06772935 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Electro-acupuncture
Description: A method of acupuncture that combines acupuncture with a certain frequency of electrical stimulation. Electrical stimulation is a mild level of stimulation intensity that is acceptable to the human body.
Study NCT05364359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Taste-test
Description: Patients will receive a dietary counseling based on a simple taste-test
Study NCT05364359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Patients will receive a dietary counseling based on a standard dietary counseling for the patient group
Study NCT04266730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANDA-VAC
Description: The primary therapeutic neoantigen vaccine product, Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine (PANDA-VAC), will be comprised of 6 peptides at a dose of 300 micrograms (µg) per peptide admixed with local adjuvant Stabilized polyriboinosinic/polyribocytidylic acid (Poly-ICLC).
Study NCT04266730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV dose every three weeks. The subject may transition to 400 mg every six weeks if, after the first scan done after start of treatment, they have a partial response or better or after two scans with stable disease or better.
Study NCT06486779 — intervention group
Intervention type: OTHER
Intervention: Ofatumumab
Description: This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
Study NCT05722652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONFIDENCE
Description: This clinic-based, multicomponent intervention consists of 3 parts:~1. Webinar training for clinicians and clinic staff about how to communicate with vaccine-hesitant parents~2. Parent-facing educational materials about COVID-19 vaccination~3. Support in creating a personalized poster campaign featuring providers and clinic staff sharing personal stories about COVID-19 vaccination
Study NCT05722652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONFIDENCE
Description: This clinic-based, multicomponent intervention consists of 3 parts:~1. Webinar training for clinicians and clinic staff about how to communicate with vaccine-hesitant parents~2. Parent-facing educational materials about COVID-19 vaccination~3. Support in creating a personalized poster campaign featuring providers and clinic staff sharing personal stories about COVID-19 vaccination
Study NCT06201507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
Study NCT06201507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days: 2 and 16 Dose: 375 mg/m2/dose.
Study NCT06201507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.
Study NCT06201507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
Study NCT06201507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m2 will be administered on days 1 and 15
Study NCT03882307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir and daclatasvir
Description: oral tablets
Study NCT04911946 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: After signing the informed consent form agreeing to participate in the study, the participants answered the questionnaire about diagnostic and therapeutic questions related to a clinical case of osteoporotic fracture in 4 scenarios: the initial care in the emergency room, at the time of discharge from hospital, during their outpatient return in 3 and 6 months.
Study NCT05412680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TOETVA
Description: TRANSORAL ENDOSCOPIC THYROIDECTOMY BY VESTIBULAR APPROACH
Study NCT05412680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional thyroidectomy
Description: conventional open thyroidectomy by cervical approach
Study NCT04321395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.
Study NCT05623462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The C-Mill virtual reality treadmill
Description: The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
Study NCT05623462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Program
Description: The Conventional Physical Therapy Program includes the following:~- Indoor open environment gait training exercises (over-ground gait training exercises.). (using obstacles, cones, stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)